Methamphetamine
As of the edition of 20 October 2026, Methamphetamine is a small molecule: marketed, first approved in 1982 (US); acts on SLC6A2, SLC6A3 and SLC6A4; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Desoxyn
- First approved
- 1 January 1982 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Ajenat Pharmaceuticals
- Registered trials
- 16, 1 stopped early
- Disease areas
- Chemically induced; Mental health; Heart and blood vessels; Inherited and neonatal
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Methamphetamine.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 11 | 8 | 2 | 1 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 4 | 3 | 2 | 1 | 0 |
| All trials | 16 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ajenat Pharmaceuticals | Acquired holder | 2024 to now |
| Abbott | Earlier holder |